Syrrx Enforces Crystallization Patent Against Oculus
Syrrx said last week that it had successfully enforced a patent against Oculus Pharmaceuticals in court. The patent, US Patent 6,296,673 entitled “Methods And Apparatus For Performing Array Microcrystallizations,” covers the crystallization of proteins in submicroliter volumes, which reduces the amount of protein required. Syrrx, which licenses the patent exclusively from The Regents of the University of California through the Lawrence Berkley National Laboratory, uses the technology in its proprietary nanovolume crystallization technology. Last April, the San Diego-based company brought a federal action against Oculus Pharmaceuticals of Birmingham, Ala., for infringing the patent. In the consent judgment, Oculus acknowledged the validity and enforceability of the patent, agreed that it had infringed it, and accepted the court’s order to stop any actions leading to infringement, according to Syrrx.
GlaxoSmithKline Takes Look at Ambit’s Profiling Technology
Ambit Biosciences said last week that GlaxoSmithKline has been evaluating its technology to characterize small molecule kinase inhibitors. Under the agreement, which started in January, San Diego-based Ambit assesses the specificity of Glaxo’s kinase inhibitors by identifying protein interactions and binding affinitities using its phage display-based screening approach.
Syn X Pharma Receives Milestone Payment from Ortho-Clinical Diagnostics
Syn X Pharma of Toronto said last week that it has received its first milestone payment from Ortho-Clinical Diagnostics for its Alzheimer’s disease diagnostics technology. The payment results from an exclusive worldwide licensing and development agreement the two companies reached last October. Syn X’s technology measures in whole blood a marker enzyme called glutamine synthetase that is released by brain cells in Alzheimer’s disease.
FDA Finds Matritech’s Bladder Cancer Test Approvable
Matritech of Newton, Mass., said last week that the Food and Drug Administration has found its NMP22 urine test approvable as an aid in diagnosing bladder cancer. As a result, the point-of-care test will be permitted for this expanded use upon successful completion of a routine manufacturing facility inspection, according to the company. The test detects the presence of NMP22, a nuclear matrix protein correlated with bladder cancer. Last summer, Matritech received FDA clearance to market the test for monitoring patients previously diagnosed with bladder cancer. Matritech develops proteomics-based diagnostic tests for the early detection of cancer using a patented technology for the isolation of nuclear matrix proteins it licenses from MIT.
Actelion to Offer OGS’ Gaucher Disease Drug in the EU
Actelion of Allschwil, Switzerland, said last week that it expects to make Oxford GlycoSciences’ inherited storage disorder drug Zavesca available in the EU within the coming months. Zavesca, which was developed by OGS, is currently available to patients with type 1 Gaucher disease in the UK. Last November, OGS granted Actelion worldwide marketing rights for Zavesca, with the exception of Israel.
Astra and Astex Collaborate
Astex Technology of Cambridge, UK, said last week that it would collaborate with AstraZeneca to develop drugs for Alzheimer’s disease. Under the agreement, AstraZeneca will fund Astex’s research program and make milestone payments of approximately $40 million, in addition to royalties based on sales of an approved product. Astex will provide an initial series of small molecules inhibitors and apply its x-ray crystallography-based approach, called fragment-based drug discovery, to identify additional drug candidates. AstraZeneca will be responsible for the clinical development of potent lead compounds. Astex already has a research agreement with AstraZeneca that focuses on solving novel cytochrome P450 crystal structures.
Genetix Reports Rising Revenues, Decreased Profit for 2002
Genetix Group of New Milton, UK, reported slightly increased revenues and decreased profits for 2002 last week.The company’s revenues climbed to £12.6 million ($20.2 million) from £12.4 million ($19.9 million) the year before. Its pre-tax profits, excluding goodwill, decreased by £0.2 million ($0.3 million) to £2.0 million ($3 million). The company invested £1.5 million ($2.4 million) in R&D last year, compared to £1.2 million ($1.9 million) the previous year. Genetix’s cash balance at the end of the year was £20.9 million ($33.5 million).The company, which has 103 employees in total, said that it will launch several new proteomics products this year.